Latest Breaking News On - James breitmeyer - Page 4 : comparemela.com

Oncternal Therapeutics, Inc (NASDAQ:ONCT) Q4 2022 Earnings Call Transcript

Operator: Greetings and welcome to the Oncternal Therapeutics, Inc. Fourth Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

United statesJames breitmeyerHartaj singhJim breitmeyerRichard vincentSalim yazjiOncternal therapeutics incAmerican society of hematology annual meetingHealth photoNational institutes of healthOncternal therapeuticsCall transcript marchFourth quarterResults conferenceInvestor relationsPrivate securities litigation reform

Oncternal Therapeutics Announces the Appointment of Jill DeSimone to the Board of Directors

Oncternal Therapeutics Announces the Appointment of Jill DeSimone to the Board of Directors
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJill desimoneJames breitmeyerInvestorsrichard vincentMediacorey davisUs oncology at merck co incAffinit therapeutics incOncternal therapeutics incNortheastern universityPraxis precision medicines incBristol myers squibbWharton school of the university pennsylvaniaFlorida cancer specialists foundationGlobal womenTeva pharmaceutical industries ltdPraxis precision medicines

Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2022

Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2022
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoUnited kingdomUniversity of california san diegoJames breitmeyerInvestorsrichard vincentMediacorey davisExchange commissionAmerican society of hematologyCalifornia institute for regenerative medicineOncternal therapeutics incUc san diego school of medicineAmerican societyCalifornia san diegoCalifornia instituteRegenerative medicine

Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2022

Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2022
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoUnited kingdomUniversity of california san diegoJames breitmeyerCorey davisRichard vincentExchange commissionAmerican society of hematologyCalifornia institute for regenerative medicineOncternal therapeutics incUc san diego school of medicineOncternal therapeuticsAmerican societyCalifornia san diegoCalifornia institute

Oncternal Therapeutics to Participate in the H C

SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the.

James breitmeyerCorey davisRichard vincentOncternal therapeutics incAnnual global investment conferenceChief executive officerSci advisorsNasdaq onctOncternal therapeutics